RxDoctor Payments Data

John Bezirganian, MD

Psychiatry · Ithaca, NYNPI 1467496349

Payments from drug & device makers

$13,984in general payments, 2019–2025

Across 177 payments — averaging $79.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$11K
  • Alkermes, Inc.$1K
  • Otsuka America Pharmaceutical, Inc.$507
  • Johnson & Johnson$355
  • Neurocrine Biosciences, Inc.$342
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$187
  • plus $716 from 7 others

What the payments were for

  • Speaking & faculty fees$9,24066%
  • Travel & lodging$881%
  • Food & beverage$4,47732%
  • Education$1791%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,984 in reported general payments places this provider in the 90th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$16,314
Medicare patients
61
Services billed
202

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole22$61,861
AristadaAripiprazole Lauroxil14$41,424
Lurasidone Hcl65$17,857
Zyprexa ZydisOlanzapine11$14,556
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl95$14,347
Divalproex Sodium ErDivalproex Sodium210$12,211
Clozapine114$10,198
ConcertaMethylphenidate Hcl11$8,498
Carbamazepine ErCarbamazepine80$7,665
Chlorpromazine Hcl18$6,451
Divalproex Sodium132$5,491
Ziprasidone Hcl46$5,243
Olanzapine263$4,477
Aripiprazole164$3,393
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine33$3,357

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena$507$61,86122 claims
Alkermes, Inc.Aristada$1,102$41,42414 claims
Johnson & JohnsonConcerta$355$8,49811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in Ithaca

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →